Amneal Pharmaceuticals (AMRX) reported $695.42 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.5%. EPS of $0.21 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $714.78 million, representing a surprise of -2.71%. The company delivered an EPS surprise of +40.00%, with the consensus EPS estimate being $0.15.While investors scrutinize revenue and earnings changes year-over-year and how they compare ...

Amneal Pharmaceuticals (AMRX) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Company Participants Anthony DiMeo - Head - IRChirag Patel - President and Co-Chief Executive OfficerChintu Patel - Co-Chief Executive OfficerTasos Konidaris - EVP & CFOLes Sulewski - VP - Biotech Equity ResearchChris Schott - Managing Director Conference Call Participants David Amsellem - Sr. Research Analyst Operator Good morning, and welcome to the Amneal Pharmaceuticals First Quarter twenty twenty five Earnings Call. I'd now li ...

Amneal Pharmaceuticals (AMRX) Q1 2025 Earnings Call May 02, 2025 08:30 AM ET Speaker0 Good morning, and welcome to the Amneal Pharmaceuticals First Quarter twenty twenty five Earnings Call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DeMayo. Speaker1 Good morning, and thank you for joining Amneal Pharmaceuticals' first quarter twenty twenty five earnings call. Today, we issued a press release reporting Q1 results. The earnings press release and presentation are available ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 40%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.15 per share when it actually produced earnings of $0.12, delivering a surprise of -20%.Over the last four quart ...

Earnings Call Q1 2025 May 2, 2025 1 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management's intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; ex ...

Exhibit 99.1 AMNEAL REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Af irming 2025 Full Year Guidance ‒ BRIDGEWATER, NJ, May 2, 2025 - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with ...

The market expects Amneal Pharmaceuticals (AMRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to b ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Debt and Liquidity - As of December 31, 2024, the company had approximately $2.6 billion in total indebtedness[234] - In January 2025, the company paid off $192.0 million of its Term Loan Due 2025, along with $0.7 million in accrued interest, using $190.0 million from new borrowings and cash on hand[234] - The company expects to make $58.8 million in principal payments on the Term Loan Due 2028 during 2025, with interest payments totaling $226.9 million for the same loan[234] - The company faces substantial liquidity risks if cash flows are insufficient to meet debt service obligations, potentially leading to asset disposals or restructuring[235] - Credit agreements impose restrictions on the company's operations, including limitations on incurring additional debt and paying dividends[236] - The company has $2.5 billion in term loans, with an Amended New Revolving Credit Facility allowing loans and letters of credit up to $495.2 million and $28.0 million, respectively[381] - As of December 31, 2024, the company had $2.48 billion in variable rate debt, including a Term Loan Due 2028 with $2.29 billion and a Term Loan Due 2025 with $192.0 million outstanding[386] Tax and Regulatory Risks - The company is subject to increased tax liabilities due to operations in multiple jurisdictions, including potential challenges from tax authorities[247] - The company recorded expenses associated with the Tax Receivable Agreement (TRA) of $50.7 million, $3.1 million, and $0.6 million for the years ended December 31, 2024, 2023, and 2022, respectively[256] - As of December 31, 2024 and 2023, the company had a TRA liability of $53.9 million and $3.7 million, respectively[256] - The unrecorded contingent TRA liability as of December 31, 2024, is approximately $133.8 million, which could significantly impact future results if deferred tax assets become realizable[256] Operational and Market Challenges - The company has significantly expanded its operations in India and may continue to grow internationally, facing regulatory and economic uncertainties[241] - Generic pharmaceuticals are experiencing regular price erosion, emphasizing the need for continual new product introductions to maintain revenue[254] - The company may face significant impairment charges if goodwill and intangible assets are determined to be impaired, which could adversely affect financial results[253] Interest Rate and Currency Risks - The company is exposed to foreign exchange rate fluctuations, particularly with the Euro and Indian Rupee, which could impact cash flow and earnings[383] - The company has entered into an interest rate lock agreement for a total notional amount of $1.3 billion to manage interest rate risk associated with its LIBOR-based borrowing[387] - The company executed an amendment to the interest rate swap, changing the reference rate from LIBOR to SOFR, with a new fixed rate of 2.7877% and a termination date extended to May 4, 2027, while maintaining a notional amount of $1.3 billion[388] - The fair value of the variable-to-fixed interest rate swap was an asset of $35.9 million as of December 31, 2024[388] - A hypothetical 100 basis point increase in the forward one-month SOFR curve could increase the fair value of the swap asset by $27.0 million, while a decrease could decrease it by $28.2 million[388] - A hypothetical 100 basis point increase or decrease in interest rates would affect the annual interest expense related to the Term Loan Due 2028 by approximately $22.9 million[389] - For the Term Loan Due 2025, a similar interest rate change would affect the annual interest expense by approximately $1.9 million[389] Dividend Policy - The company does not anticipate paying any cash dividends in the foreseeable future, focusing instead on retaining earnings for business growth[267] Inflation Impact - The company expects no material impact from inflation for the year ending December 31, 2025, although rising costs could adversely affect future operating results[384]

Q4 2024 Earnings Call Q4 2024 earnings call Agenda 1 Strategy & Business Update Chirag and Chintu Patel, Co-founders and Co-CEOs 2 Financial Results Tasos Konidaris, EVP & CFO 3 Q&A Chirag Patel, Co-CEO and President Joe Renda, SVP - Specialty 3 Cautionary statement on forward looking statements Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking ...